Form 4: Regeneron Director Christine Poon Exercises Options and Sells Shares

Director Christine Poon exercised stock options and sold shares of Regeneron Pharmaceuticals on August 15, 2024.

Summary

• On August 15, 2024, Christine Poon, a director of Regeneron Pharmaceuticals, exercised non-qualified stock options to acquire 10,838 shares of common stock at a price of $413.33 per share.
• Following the exercise of these options, Poon sold a total of 10,838 shares of Regeneron common stock in multiple transactions at prices ranging from $1,155.72 to $1,161.32.
• The sales were executed at volume-weighted average prices.
• After these transactions, Poon directly owns 2,172 shares of Regeneron common stock.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common among corporate executives and directors. These filings are monitored by investors to gain insights into management's perspective on the company's stock and future prospects.

Comparison to Industry Standards

• Form 4 filings are standard practice for corporate insiders and are publicly available for scrutiny.
• The transactions are within the normal course of executive compensation and portfolio management.
• Comparable companies would have similar filings when their executives exercise options and sell shares.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• The impact is likely minimal given the relatively small number of shares involved compared to the company's overall market capitalization.

Key Dates